We partner with BioMed Central's open access journal, Molecular Neurodegeneration (MN), which is the official journal of BrightFocus. The open access publishing model provides free articles to the general public, as well as scientists, clinicians, and other healthcare practitioners.
MN publishes peer-reviewed, original scientific research on the causes of neurodegenerative diseases, such as Alzheimer's or Parkinson' and on the pre-clinical testing of potential therapies for these devastating diseases.
MN has an impact factor of 14.195 for 2020, with a five year impact factor of 11.684, reflecting the sustained impact of our journal. MN remains the highest ranked open access neuroscience journal in the Journal Citation Reports (JCR).